News — TAMPA, Fla. (Oct. 31, 2011) 鈥� Graft-versus-host disease (GVHD) is a serious risk in many kinds of cell transplants, including for stem cell transplants carried out when stem cells are partially depleted of conventional T cells, which play an important role in the immune system. Now, researchers at Moffitt Cancer Center have tested a process by which T regulatory cells (Tregs) can be 鈥渆xpanded鈥� to help prevent GVHD.
鈥淭regs play a dominant role in transplantation tolerance,鈥� said Claudio Anasetti, M.D., corresponding author of a study carried out by a team of Moffitt investigators and published in a recent issue of the journal Blood.
鈥淎doptive transfer of freshly isolated human Tregs has prevented GVHD in patients treated with allogeneic (other than self-donated) stem cell transplants. However, some transplants will require a greater number of Tregs that can only be obtained through expanding Tregs outside of the body.鈥�
The researchers suggest that therapeutic applications will require Tregs to be expanded by more than a hundredfold.
鈥淭here is a need to improve on Treg expansion protocols before allo-specific Tregs can be brought into the clinic,鈥� said Anasetti, chair of the Department of Blood & Marrow Transplant at Moffitt.
The authors note that a recently adopted expansion process has used dendritic cells to activate Tregs.
鈥淒endritic cells have been identified as having unique capabilities for expanding Tregs,鈥� cited Anasetti, whose work focuses on preventing GVHD in mouse models and in humans.
To carry out the present study, Anasetti and his fellow researchers adopted a one-step process to expand allo-specific Tregs by dendritic cell stimulation.
鈥淥ur work opens an opportunity to study tissues as sources of antigens for indirect presentation to activate and expand therapeutic Tregs,鈥� concluded Anasetti. 鈥淚f effective, this approach could prevent GVHD while sparing, at least in part, graft-versus-leukemia or graft-versus-tumor responses.鈥� About Moffitt Cancer CenterFollow Moffitt on Facebook: Follow Moffitt on Twitter: @Moffitt麻豆传媒Follow Moffitt on YouTube: MoffittNews
Located in Tampa, Moffitt Cancer Center is Florida's only NCI Comprehensive Cancer Center, a designation that recognizes Moffitt's excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 14 affiliates in Florida, one in Georgia, one in Pennsylvania and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country's leading cancer centers, and is listed in U.S. 麻豆传媒 & World Report as one of "America's Best Hospitals" for cancer. Moffitt marks a very important anniversary in 2011 - 25 years committed to one mission: to contribute to the prevention and cure of cancer.
RSS